Menlo Park, CA-based Tricida, Inc is a clinical-stage, a biopharmaceutical company focused on the discovery and development of first-in-class chronic therapies for patients with chronic kidney disease.
Tricida has raised a $55M Series C round. This Series C financing was led by Longitude Capital, with participation, Vivo Capital, OrbiMed, Sibling Capital Ventures and Limulus Venture Partners.“Establishing clinical proof of concept for TRC101 is ahead of schedule,” said Gerrit Klaerner, Ph.D., Tricida’s CEO, President, and Board Member. “This rapid progress has allowed us to expand our already very strong syndicate of investors. We welcome Longitude and Vivo to the Tricida team.”
“I am pleased to support the development of a first-in-class clinical candidate. We see tremendous value in bringing a treatment to market that has the potential to be disease-modifying in CKD,” said David Hirsch, M.D., Ph.D., Managing Director at Longitude. The company was formerly known as Trilypsa, Inc. Tricida’s lead program is TRC101, a chronic treatment for complications of renal disease. Tricida has raised a $10M Series A round of financing in Q1 of 2014 and a $30M Series B in Q1 of 2015. The company did not disclose anything about going to public market yet.
TRICIDA TOTAL FUNDING : 99.51M IN 4 ROUNDS : [ Via Venture Pulse Data ]
|Date||Funding Amount||Funding Round||Lead VC/Investor|
|Jul, 2016||$55M||Series C||Longitude Capital|
|Mar, 2015||$30M||Series B||Vivo Capital|
|Sep, 2014||$10M||Series A||OrbiMed|